Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial
Phase of Trial: Phase IV
Latest Information Update: 19 Mar 2019
Price : $35 *
At a glance
- Drugs Rifaximin (Primary) ; Lactulose
- Indications Bacterial infections; Hepatic encephalopathy
- Focus Therapeutic Use
- 19 Mar 2019 Results of a pooled analysis of 2 randomised trials investigating Rifaximin And Lactulose Combination Therapy Versus Lactulose Alone For Prevention Of Overt Hepatic Encephalopathy Recurrence will be presented at the Hospital Medicine 2019, the annual conference of the Society of Hospital Medicine, being held in National Harbor, Md., March 24-27, 2019.
- 15 Oct 2013 Results published in the Annals of Internal Medicine.
- 31 Jul 2013 New trial record